Crown Laboratories Acquires Revance Therapeutics in $924M Merger

Crown Aesthetics (Crown Laboratories) Acquires Select Assets from Healeon LLC (Bimini Health Tech)

July 23, 2024

Medical Devices

Crown Aesthetics, a Crown Laboratories company, has acquired select assets and technology from Healeon LLC, a subsidiary of Bimini Health Tech, to strengthen its ProGen PRP Eclipse platelet-rich plasma (PRP) offering. The asset purchase expands Crown's PRP device portfolio, supports new product development, and aims to extend Crown's geographic and production capabilities in the regenerative and aesthetic medicine markets.

Crown Laboratories Acquires StriVectin from L Catterton

August 26, 2021

Consumer Products

Crown Laboratories, a Hildred Capital portfolio company, has entered into a definitive agreement to acquire StriVectin from L Catterton. StriVectin will operate as a wholly owned subsidiary within Crown's new Premium Skincare Division, with its president Cori Aleardi joining Crown's executive team; the deal was expected to close by mid-September 2021.

Crown Laboratories Acquires Eclipse Medcorp's Aesthetics Assets

May 24, 2022

Medical Devices

Crown Laboratories has acquired the global, aesthetics-focused assets of Eclipse Medcorp, LLC, expanding Crown's aesthetics product portfolio and integrating Eclipse's devices into its Aesthetics business unit. The deal aims to broaden Crown's product offerings to aesthetics providers domestically and internationally and preserve service and medical-education support for Eclipse customers under Crown.

Revive Therapeutics Agrees to Acquire Psilocin Pharma Corp.

February 11, 2020

Pharmaceuticals

Revive Therapeutics Ltd. entered into a letter of intent to acquire all issued and outstanding securities of Psilocin Pharma Corp. for an aggregate purchase price of $2.75 million to be satisfied by issuing 55 million common shares of Revive (deemed $0.05/share). Revive deposited 10 million shares ($500,000) into escrow as a deposit; the closing is subject to due diligence and execution of a definitive share exchange agreement.

Avance Clinical Acquires C3 Research Associates to Expand into North America

September 6, 2022

Healthcare Services

Avance Clinical, a PE-backed Australian CRO, has acquired North American CRO partner C3 Research Associates to expand its later‑phase clinical trial capabilities and establish a US presence. Backed by private equity firm The Riverside Company, Avance will integrate C3 into its GlobalReady model and invest in growing its North American team to support biotechs transitioning from early‑phase studies in Australia/New Zealand to later phases in the US.

Eli Lilly and Company to Acquire Prevail Therapeutics

December 15, 2020

Biotechnology

Eli Lilly and Company announced a definitive agreement to acquire Prevail Therapeutics for $22.50 per share in cash, plus a non-tradable contingent value right (CVR) worth up to $4.00 per share, for total consideration of up to approximately $1.04 billion. The acquisition is intended to establish a gene therapy program within Lilly anchored by Prevail’s AAV9-based neuroscience pipeline. Lilly expects the transaction to close in the first quarter of 2021, subject to customary closing conditions and regulatory approvals.